Literature DB >> 2344173

Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infections.

J S Bradley1, J D Connor, L S Compogiannis, L L Eiger.   

Abstract

Health care workers (HCW) are exposed to ribavirin aerosol during therapy of infants with respiratory syncytial virus infections. To assess the degree of HCW exposure, we analyzed air samples from patient rooms and HCW personal breathing zones during ribavirin aerosol delivery by ventilator (two samples), oxygen hood (two samples), and a new vacuum exhaust hood (four samples). HCW exposure to ribavirin during aerosol delivery by ventilator or vacuum exhaust hood system was substantially lower than HCW exposure during aerosol delivery by oxygen hood in rooms with adequate ventilation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2344173      PMCID: PMC171665          DOI: 10.1128/AAC.34.4.668

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease.

Authors:  W J Rodriguez; H W Kim; C D Brandt; R J Fink; P R Getson; J Arrobio; T M Murphy; V McCarthy; R H Parrott
Journal:  Pediatr Infect Dis J       Date:  1987-02       Impact factor: 2.129

2.  Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease.

Authors:  C B Hall; J T McBride; C L Gala; S W Hildreth; K C Schnabel
Journal:  JAMA       Date:  1985-12-06       Impact factor: 56.272

3.  Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin.

Authors:  R K Austin; P E Trefts; M Hintz; J D Connor; M F Kagnoff
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic.

Authors:  D A Conrad; J C Christenson; J L Waner; M I Marks
Journal:  Pediatr Infect Dis J       Date:  1987-02       Impact factor: 2.129

Review 5.  Cross-species extrapolations and the biologic basis for safety factor determinations in developmental toxicology.

Authors:  E M Johnson
Journal:  Regul Toxicol Pharmacol       Date:  1988-03       Impact factor: 3.271

6.  Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections.

Authors:  W J Rodriguez; R H Bui; J D Connor; H W Kim; C D Brandt; R H Parrott; B Burch; J Mace
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

7.  Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.

Authors:  C B Hall; J T McBride; E E Walsh; D M Bell; C L Gala; S Hildreth; L G Ten Eyck; W J Hall
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245

8.  Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants.

Authors:  L H Taber; V Knight; B E Gilbert; H W McClung; S Z Wilson; H J Norton; J M Thurson; W H Gordon; R L Atmar; W R Schlaudt
Journal:  Pediatrics       Date:  1983-11       Impact factor: 7.124

  8 in total
  4 in total

1.  Ribavirin: is there a risk to hospital personnel? Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1991-02-01       Impact factor: 8.262

2.  The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.

Authors:  Tongna Zhu; Chuanlong Zhang; Li Yu; Jingxian Chen; Huan Qiu; Weiwei Lyu; Shenghai Huang
Journal:  Virol Sin       Date:  2015-10-22       Impact factor: 4.327

Review 3.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

4.  Antiviral agents against respiratory viruses.

Authors:  Cecile L Tremblay
Journal:  Clin Microbiol Newsl       Date:  2001-12-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.